The short answer
In the 72-week SURMOUNT-5 study, tirzepatide produced greater average weight loss than semaglutide. It compared tirzepatide 10/15 mg with semaglutide 1.7/2.4 mg injections, according to the tolerated dose. That result does not compare Wegovy 7.2 mg or tablets, and it does not predict an individual result. EMA Mounjaro product information, section 5.1: SURMOUNT-5.
The right choice is not simply the strongest medication. It depends on your budget, medical history, side-effect tolerance, current stock, and what a prescribing doctor thinks is appropriate.
Comparison and official information checked 8 October 2026. Price observations remain dated 12 October 2026; authorisation does not establish Irish stock or reimbursement.
Price ranges above come from the dated, source-linked price list. Packs, strengths, supply periods and inclusions differ; a four-week supply is not a calendar month. Add consultation, follow-up and other required charges using the cost planner.
Current EMA Wegovy information allows a prescriber to consider 7.2 mg after at least four weeks at 2.4 mg for adults whose BMI was at least 30 when treatment began. This is not a reason to change your own dose or a statement that the dose is available from an Irish pharmacy. See the full criteria in EMA Wegovy product information, section 4.2.
Brand, ingredient and indication are different things
The brand is the product name; the ingredient is the active substance; the indication describes its authorised use and patient group. Mounjaro contains tirzepatide and has EU indications for type 2 diabetes and adult weight management, with different criteria. Wegovy contains semaglutide and has a weight-management indication. Ozempic and Rybelsus also contain semaglutide but are authorised for type 2 diabetes, rather than weight management. A shared ingredient does not make products, strengths or instructions interchangeable.
Check the full current indication in the authorised information below, including age, BMI and other requirements. See also EMA's records for Ozempic and Rybelsus. A licence and an Irish funding decision are separate: see the HSE reimbursement guide.
Questions to discuss about Mounjaro
- How relevant is the trial population and dose to your own treatment goals and medical history?
- How will your prescriber assess response, tolerability and any other medicines?
- What would the prescribed strength and continuing clinical support cost on your actual route?
Questions to discuss about Wegovy
- Which formulation and authorised treatment plan is the prescriber considering?
- How will response and side effects be reviewed before any treatment change?
- Can the pharmacy supply the prescribed product, and what is the complete repeat cost?
Why switching or restarting needs clinical advice
The reason for a gap, previous side effects and the exact product matter. Wegovy's authorised information says a lower starting dose should be considered when more doses have been missed. Mounjaro has its own missed-dose instructions; do not transfer rules from one medicine to another. Tell the prescribing team your last dose date, dose and formulation, why treatment stopped, symptoms and other medicines. Ask them to confirm the restart or switch plan and follow-up. A leaflet's single missed-dose rule is not a universal restart schedule after a longer interruption.
Do not overlap medicines, improvise a dose conversion or restart at an old dose without checking the clinical plan. Your prescriber should set the timing, dose and side-effect plan.
Compare the authorised information
These EMA documents contain the full professional information and patient leaflets:
Match the formulation and pack first. Compare professional sections 4.1 (indications), 4.2 (administration), 4.3–4.5 (contraindications, warnings and interactions) and 4.8 (side effects), then read the matching patient leaflet. Wegovy's file includes both tablets and injections. These sources help you prepare questions; they cannot decide which medicine is suitable for you.
Compare Irish providers
The providers below offer online consultation pathways for GLP-1 medications in Ireland. Availability and pricing can change, so use the table as a shortlist and confirm details directly.